Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

MGNX

Macrogenics Inc

Dec 11 • 04:00PM ET

3.41

Dollar change +0.07
Percentage change 2.10	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD MRNA ALNY EXEL BGNE AGEN INCY ZLAB UBX DLTH

| Held by: VTI IWM VXF IWO IBB SCHA VTWO VHT IWC DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.57	Insider Own	7.78%	Shs Outstand	62.76M	Perf Week	-2.29%
Market Cap	214.02M	Forward P/E	-	EPS next Y	-2.20	Insider Trans	0.00%	Shs Float	57.88M	Perf Month	-22.32%
Income	-97.62M	PEG	-	EPS next Q	-0.37	Inst Own	84.43%	Short Float	9.01%	Perf Quarter	-5.54%
Sales	141.33M	P/S	1.51	EPS this Y	-697.81%	Inst Trans	-8.76%	Short Ratio	8.59	Perf Half Y	-31.66%
Book/sh	1.91	P/B	1.78	EPS next Y	-83.92%	ROA	-32.30%	Short Interest	5.21M	Perf Year	-59.69%
Cash/sh	3.19	P/C	1.07	EPS next 5Y	-	ROE	-62.17%	52W Range	2.95 - 21.88	Perf YTD	-64.55%
Dividend Est.	-	P/FCF	-	EPS past 5Y	48.88%	ROI	-65.33%	52W High	-84.41%	Beta	2.03
Dividend TTM	-	Quick Ratio	3.69	Sales past 5Y	15.77%	Gross Margin	89.84%	52W Low	15.55%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	3.75	EPS Y/Y TTM	-295.28%	Oper. Margin	-75.78%	RSI (14)	45.33	Volatility	5.51% 6.49%
Employees	339	Debt/Eq	0.28	Sales Y/Y TTM	16.68%	Profit Margin	-69.07%	Recom	2.36	Target Price	7.29
Option/Short	Yes / Yes	LT Debt/Eq	0.24	EPS Q/Q	218.23%	Payout	-	Rel Volume	0.85	Prev Close	3.34
Sales Surprise	26.37%	EPS Surprise	325.53%	Sales Q/Q	964.81%	Earnings	Nov 05 AMC	Avg Volume	606.74K	Price	3.41
SMA20	-1.91%	SMA50	-7.78%	SMA200	-52.10%	Trades		Volume	517,947	Change	2.10%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-07-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-01-24	Downgrade	BTIG Research	Buy → Neutral
Jul-31-24	Downgrade	Guggenheim	Buy → Neutral
Jul-31-24	Downgrade	B. Riley Securities	Buy → Neutral	$18 → $5
May-10-24	Downgrade	TD Cowen	Buy → Hold
May-10-24	Downgrade	Stifel	Buy → Hold	$29 → $7
May-10-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$24 → $8
Apr-26-24	Initiated	B. Riley Securities	Buy	$25
Apr-09-24	Upgrade	TD Cowen	Hold → Buy
Mar-04-24	Reiterated	BTIG Research	Buy	$12 → $24
Feb-14-24	Downgrade	H.C. Wainwright	Buy → Neutral	$12 → $14
Dec-20-23	Upgrade	Citigroup	Neutral → Buy	$7 → $13
Nov-07-23	Upgrade	Guggenheim	Neutral → Buy	$12
Mar-17-23	Downgrade	Guggenheim	Buy → Neutral
Nov-22-22	Downgrade	Cowen	Outperform → Market Perform
Nov-14-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$5.70 → $16
Jul-18-22	Downgrade	SMBC Nikko	Outperform → Neutral	$5
Jul-11-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$31 → $4
May-04-22	Downgrade	Guggenheim	Buy → Neutral
Feb-28-22	Upgrade	Citigroup	Neutral → Buy	$23 → $21

Show Previous Ratings

Dec-02-24 04:30PM	MacroGenics to Participate in Upcoming Investor Conference (GlobeNewswire) -6.78%
Nov-06-24 04:30PM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.14% +6.44%
08:51AM	Q3 2024 MacroGenics Inc Earnings Call (Thomson Reuters StreetEvents)
02:25AM	Macrogenics Inc (MGNX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Developments (GuruFocus.com)
Nov-05-24 10:15PM	MacroGenics (MGNX) Q3 2024 Earnings Call Transcript (Motley Fool)
08:00PM	Loading…
08:00PM	Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings (Zacks)
07:30PM	MacroGenics (MGNX) Beats Q3 Earnings and Revenue Estimates (Zacks)
06:26PM	MacroGenics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-04-24 07:13AM	Earnings To Watch: Macrogenics Inc (MGNX) Reports Q3 2024 Result (GuruFocus.com)
Oct-30-24 07:30AM	MacroGenics Announces Leadership Transition (GlobeNewswire)
Oct-29-24 04:30PM	MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call (GlobeNewswire) -5.11%
Oct-23-24 08:41AM	TerSera acquires global rights to MacroGenics' MARGENZA for breast cancer treatment (Pharmaceutical Business Review)
Oct-22-24 07:30AM	MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA (Business Wire)
Sep-24-24 05:45AM	MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX (PR Newswire)
11:05AM	Loading…
Sep-23-24 11:05AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile) -6.71%
Sep-20-24 05:06AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Sep-19-24 01:29PM	MacroGenics, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights MGNX (GlobeNewswire)
Sep-17-24 08:30AM	MacroGenics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MGNX (PR Newswire)
05:45AM	Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX (PR Newswire)
Sep-15-24 03:00AM	MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 (GlobeNewswire)
Sep-13-24 08:34AM	Do Options Traders Know Something About MacroGenics (MGNX) Stock We Don't? (Zacks)
Sep-11-24 08:30AM	MacroGenics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MGNX (PR Newswire)
Sep-08-24 07:10PM	MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024 (GlobeNewswire)
Sep-04-24 03:29PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Sep-03-24 05:45AM	Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX (PR Newswire) -6.55%
Sep-02-24 02:05PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire)
Aug-30-24 09:43AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Aug-29-24 01:09PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire)
Aug-27-24 10:48AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
03:40PM	Loading…
Aug-26-24 03:40PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire)
Aug-22-24 03:16PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire) -7.50%
01:17PM	MacroGenics, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights MGNX (GlobeNewswire)
Aug-21-24 07:05AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Aug-19-24 04:37PM	MacroGenics (MGNX) Under Fire as Analyst Downgrade Deepens Crisis Hagens Berman (GlobeNewswire) +9.91%
Aug-17-24 03:29PM	Kessler Topaz Meltzer & Check, LLP Encourages MacroGenics, Inc. Investors with Losses to Contact the Firm (GlobeNewswire)
Aug-16-24 05:45AM	MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX (PR Newswire)
04:26AM	MacroGenics (MGNX) Under Fire as Analyst Downgrade Deepens Crisis - Hagens Berman (Newsfile)
Aug-15-24 02:19PM	MacroGenics (MGNX) Under Fire as Analyst Downgrade Deepens Crisis Hagens Berman (GlobeNewswire)
Aug-14-24 12:19PM	MacroGenics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights MGNX (GlobeNewswire) -5.38%
Aug-13-24 02:31PM	MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit - Hagens Berman (Newsfile) +5.37%
12:45AM	MGNX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire)
Aug-12-24 10:20AM	MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit Hagens Berman (GlobeNewswire)
Aug-08-24 11:31AM	MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit Hagens Berman (GlobeNewswire)
Aug-07-24 08:53AM	MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit - Hagens Berman (Newsfile) -7.14%
Aug-06-24 09:30PM	Compared to Estimates, MacroGenics (MGNX) Q2 Earnings: A Look at Key Metrics (Zacks)
05:30PM	MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:33PM	MacroGenics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 04:10PM	MacroGenics Provides Vobramitamab Duocarmazine Update (GlobeNewswire) -28.38%
04:01PM	MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte (GlobeNewswire)
Jul-24-24 01:29PM	MacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash Hagens Berman (GlobeNewswire)
Jul-16-24 03:57PM	MacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash Hagens Berman (GlobeNewswire) +11.49%
Jul-10-24 05:19PM	MacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash Hagens Berman (GlobeNewswire) +8.90%
Jul-03-24 05:34PM	MacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash Hagens Berman (GlobeNewswire)
Jun-20-24 01:28PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire)
Jun-13-24 12:29PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire) -6.21%
Jun-11-24 07:45AM	MacroGenics to Participate in Upcoming Investor Conference (GlobeNewswire) +7.64%
May-29-24 12:44PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire)
May-25-24 12:00PM	3 Biotech Stocks That Could Be Millionaire-Makers: May Edition (InvestorPlace)
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire) -14.75%
May-16-24 12:59PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire) +8.70%
May-13-24 12:30PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire) +32.33%
07:30AM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-10-24 06:01PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire) -77.44%
04:51PM	Macrogenics Stock Drops 77% After Study Deaths (The Wall Street Journal)
03:29PM	Macrogenics Inc (MGNX) Q1 2024 Earnings: Misses Revenue Estimates Amidst Ongoing Clinical ... (GuruFocus.com)
03:17PM	MacroGenics, Inc. (NASDAQ:MGNX) Q1 2024 Earnings Call Transcript (Insider Monkey)
02:01PM	Top Midday Decliners (MT Newswires)
08:35AM	Why Is Macrogenics (MGNX) Stock Down 69% Today? (InvestorPlace)
07:48AM	Top Premarket Decliners (MT Newswires)
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
07:15AM	BMO Downgrades MacroGenics to Market Perform From Outperform, Price Target at $8 (MT Newswires)
07:14AM	Stifel Downgrades MacroGenics to Hold (MT Newswires)
07:12AM	TD Cowen Downgrades MacroGenics to Hold From Buy (MT Newswires)
07:12AM	MacroGenics Says Five Patients Died in Cancer Study (MT Newswires)
06:02AM	MacroGenics' stock crashes after 5 deaths seen in ADC trial (FierceBiotech.com)
04:57AM	MacroGenics Q1 Loss Widens, Revenue Falls (MT Newswires)
02:15AM	MacroGenics (MGNX) Q1 2024 Earnings Call Transcript (Motley Fool)
May-09-24 08:57PM	MGNX Stock Earnings: Macrogenics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:10PM	MacroGenics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data (GlobeNewswire)
May-03-24 07:30AM	MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call (GlobeNewswire)
May-01-24 10:05AM	Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 (PR Newswire) +5.21%
Apr-26-24 08:00AM	B. Riley Securities Initiates MacroGenics With Buy Rating, $25 Price Target (MT Newswires)
Apr-03-24 04:30PM	MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures (GlobeNewswire) +30.07%
Mar-14-24 08:18AM	MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-08-24 07:19AM	Q4 2023 MacroGenics Inc Earnings Call (Thomson Reuters StreetEvents) -15.02%
12:30AM	MacroGenics (MGNX) Q4 2023 Earnings Call Transcript (Motley Fool)
Mar-07-24 10:42PM	Macrogenics Inc (MGNX) Reports Strong Financial Position and Advancements in Cancer Treatment ... (GuruFocus.com)
09:55PM	MGNX Stock Earnings: Macrogenics Misses EPS for Q4 2023 (InvestorPlace)
05:30PM	MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:01PM	MacroGenics Provides Update on Corporate Progress and 2023 Financial Results (GlobeNewswire)
Mar-06-24 11:29PM	Insider Sell: COO Eric Risser Sells 41,159 Shares of Macrogenics Inc (MGNX) (GuruFocus.com)
Mar-01-24 05:48PM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.24% +8.71%
Feb-29-24 10:00AM	Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-27-24 05:45PM	MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call (GlobeNewswire)
Feb-02-24 04:30PM	MacroGenics to Participate in Upcoming Investor Conference (GlobeNewswire) +8.45%
07:19AM	MacroGenics (MGNX) Surges 6.8%: Is This an Indication of Further Gains? (Zacks)

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SIEGEL JAY PHILIP	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:34 PM
HEIDEN WILLIAM K	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:34 PM
Jackson Scott Thomas	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:34 PM
STUMP DAVID C	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:33 PM
O'Brien Federica F.	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:33 PM
Liu Margaret	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:33 PM
Chhabra Meenu	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:33 PM
Ferrante Karen Jean	Director	May 20 '24	Option Exercise	0.00	4,500	0	4,500	May 22 04:32 PM
HURWITZ EDWARD	Director	May 20 '24	Option Exercise	0.00	4,500	0	37,574	May 22 04:32 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Apr 04 '24	Option Exercise	4.82	42,500	204,850	51,395	Apr 08 06:07 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Apr 04 '24	Sale	15.55	51,395	799,148	0	Apr 08 06:07 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Mar 06 '24	Option Exercise	10.90	19,625	213,875	28,520	Mar 08 04:14 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Mar 06 '24	Sale	21.50	19,625	421,938	8,895	Mar 08 04:14 PM
Risser Eric Blasius	Chief Operating Officer	Mar 04 '24	Option Exercise	10.15	15,000	152,250	80,059	Mar 06 04:20 PM
Risser Eric Blasius	Chief Operating Officer	Mar 04 '24	Sale	19.76	41,159	813,501	38,900	Mar 06 04:20 PM
Spitznagel Thomas	Sr VP, Technical Ops	Mar 04 '24	Option Exercise	11.50	10,000	115,000	18,316	Mar 06 04:19 PM
Spitznagel Thomas	Sr VP, Technical Ops	Mar 04 '24	Sale	20.00	10,000	200,000	8,316	Mar 06 04:19 PM
Karrels James	SVP, CFO and Secretary	Mar 04 '24	Sale	20.50	30,000	615,000	171,452	Mar 06 04:18 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Feb 26 '24	Sale	17.22	16,124	277,655	8,895	Feb 28 04:20 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Feb 22 '24	Option Exercise	0.00	26,250	0	35,145	Feb 26 04:27 PM
Bonvini Ezio	Sr VP, Research & CSO	Feb 22 '24	Option Exercise	0.00	28,125	0	110,258	Feb 26 04:26 PM
Eck Stephen L.	Chief Medical Officer	Feb 15 '24	Option Exercise	0.00	16,670	0	16,670	Feb 20 06:41 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Feb 15 '24	Option Exercise	0.00	13,336	0	13,336	Feb 20 06:05 PM
Koenig Scott	President and CEO	Feb 15 '24	Option Exercise	0.00	42,341	0	1,091,977	Feb 20 06:04 PM
Cilinski Lynn	VP, Controller and Treasurer	Feb 15 '24	Option Exercise	0.00	6,668	0	8,591	Feb 20 06:04 PM
Risser Eric Blasius	Chief Operating Officer	Feb 15 '24	Option Exercise	0.00	16,670	0	70,938	Feb 20 06:04 PM
Karrels James	SVP, CFO and Secretary	Feb 15 '24	Option Exercise	0.00	15,003	0	206,779	Feb 20 06:04 PM
Spitznagel Thomas	Sr VP, Technical Ops	Feb 15 '24	Option Exercise	0.00	13,336	0	13,336	Feb 20 06:03 PM
Bonvini Ezio	Sr VP, Research & CSO	Feb 15 '24	Option Exercise	0.00	16,670	0	88,004	Feb 20 06:03 PM
Bonvini Ezio	Sr VP, Research & CSO	Feb 07 '24	Sale	18.00	3,334	60,012	71,334	Feb 07 04:19 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Feb 05 '24	Option Exercise	11.11	76,251	847,355	76,251	Feb 07 04:17 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Feb 05 '24	Sale	16.50	76,251	1,258,142	0	Feb 07 04:17 PM
Bonvini Ezio	Sr VP, Research & CSO	Feb 01 '24	Sale	15.00	13,316	199,740	74,668	Feb 02 04:21 PM
Bonvini Ezio	Sr VP, Research & CSO	Jan 19 '24	Sale	12.00	13,316	159,792	87,984	Jan 22 04:57 PM
Bonvini Ezio	Sr VP, Research & CSO	Dec 20 '23	Sale	10.08	18,880	190,310	101,300	Dec 21 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MGNX

Macrogenics Inc

Upgrade your FINVIZ experience